Market closedADR

Novo Nordisk/$NVO

14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX

About Novo Nordisk

With roughly one third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (constituting roughly 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.

Ticker

$NVO

Trading on

NYSE

Industry

Pharmaceuticals

Headquarters

Bagsvaerd, Denmark

Employees

71,880

Novo Nordisk Metrics

BasicAdvanced
$470B
Market cap
35.82
P/E ratio
$2.99
EPS
0.17
Beta
$1.03
Dividend rate
0.68%
Dividend yield
$470B
0.17
$148.15
$96.53
5.7M
$1.03
0.937
0.742
42.691
47.271
46.60%
44.90%
22.49%
88.73%
35.818
12.511
27.85
50.84
50.502
0.96%
0.68%
26.15%
26.84%
26.21%
28.51%
28.42%

What the Analysts think about Novo Nordisk

Analyst Ratings

Analyst ratings (Buy, Hold, Sell) for Novo Nordisk stock.

Novo Nordisk Financial Performance

Income Statement

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

Novo Nordisk Earnings Performance

Earnings per share (EPS)

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $NVO

$

Sign up or log in to buy
Capital at risk
Market closedADR

Upcoming events

No upcoming events

FAQs

What’s the current market cap for Novo Nordisk stock?

Novo Nordisk (NVO) has a market cap of $470B as of December 15, 2024.

What is the P/E ratio for Novo Nordisk stock?

The price to earnings (P/E) ratio for Novo Nordisk (NVO) stock is 35.82 as of December 15, 2024.

Does Novo Nordisk stock pay dividends?

Yes, the Novo Nordisk (NVO) stock pays dividends to shareholders. As of December 15, 2024, the dividend rate is $1.02575 and the yield is 0.68%. Novo Nordisk has a payout ratio of 46.6% on a trailing twelve-month basis.

When is the next Novo Nordisk dividend payment date?

The next Novo Nordisk (NVO) dividend payment date is unconfirmed.

What is the beta indicator for Novo Nordisk?

Novo Nordisk (NVO) has a beta rating of 0.17. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.